BioHarvest Sciences Inc. Common Stock

BHST • Agricultural Inputs

$1.68

▼ -0.12 (-6.67%)

Precio actual

ResultadosÚltimo reporte: 31 mar 2026

PERFIL DE MAYOR RIESGOPrecauciónConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Conviene actuar con cautela. Los ratios recientes muestran debilidades que pueden limitar el retorno si los fundamentales no mejoran.

Capitalización

$38.08M

Crecimiento

—

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Crecimiento positivo de ingresos · 82.5%Nivel de deuda manejable · 0.55Liquidez saludable · 3.97Rentabilidad débil

Datos financieros hasta: 31 mar 2026, 12:00 a.m. UTCÚltima actualización de earnings: 14 may 2026, 12:00 a.m. UTCÚltima actualización del perfil: 13 ago 2026, 1:02 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$1.68

Change-6.67%

Shares Out22.67M

Market Cap$38.08M

Enterprise Value$25.08M

52W Range1.82 - 12.80

Beta1.37

P/E-3.33

P/S1.08

P/B1.65

P/FCF-3.91

EV/Sales0.71

Price$1.68

Change-6.67%

Shares Out22.67M

Market Cap$38.08M

Enterprise Value$25.08M

52W Range1.82 - 12.80

Beta1.37

P/E-3.33

P/S1.08

P/B1.65

P/FCF-3.91

EV/Sales0.71

EV/EBITDA-3.75

EV/FCF-2.57

Earnings Yield-30.04%

FCF Yield-25.58%

Dividend Yield0.00%

Gross Margin59.34%

Oper. Margin-16.16%

Profit Margin-32.27%

Debt/Eq0.55

Current Ratio3.97

Quick Ratio3.38

Target$5.00

Target Upside197.62%

Target Median$5.00

Target Range5.00 - 5.00

Volume41.45K

Avg Volume42.00K

EPS Surprise0.02

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

73/100

Potencial de crecimiento

Ingresos y expansión

95/100

Atractivo del precio

Barata o cara hoy

76/100

Por qué este puntaje▼

Crecimiento positivo de ingresos · 82.5%Nivel de deuda manejable · 0.55Liquidez saludable · 3.97Rentabilidad débil

Analyst view

Analyst sentiment and price target

BHST

Analyst sentiment

Based on 3 analyst votes · 2026-10-21

100/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-13

Bajo

$5.00

Promedio

$7.50

Mediana

$7.50

Alto

$10.00

Resumen de la compañía

IPO: 1/8/2021

Industria: Agricultural Inputs

P/B i: 1.65

Deuda / Patrimonio i: 0.55

Margen operativo: -16.16%

Margen neto: -32.27%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.55

Ratio corriente: 3.97

Ratio rápido: 3.38

Estado: Good

🧾

No hay actividad interna

No hay transacciones internas recientes disponibles.

Sobre la compañía

BioHarvest Sciences Inc. Common Stock

BioHarvest Sciences Inc. functions as a biotechnology firm with operations segmented into Nutraceuticals and Pharmaceuticals. A key innovation is its proprietary botanical synthesis platform technology, which allows for the cultivation of active ingredients found within plant enzymes or cells. The company harnesses this advanced technology to craft evidence-based and clinically validated therapeutic products for both its nutraceutical and pharmaceutical offerings. Beyond its own development, it also provides contract development and manufacturing services. Its product portfolio includes various wellness items, notably VINIA, a dietary supplement derived from red grape cells, which delivers the full spectrum of polyphenols naturally present in red grapes. The company conducts business in Israel and the United States, with its corporate base in Vancouver, Canada.

Fuente - Link

Competidores

ACNT AVD BIOX CMT FF FRD LVRO MERC TRX USGO

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

BioHarvest takes second plant-cell asset to commercial readiness

BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said on Tuesday that Olive Cell, an olive-derived plant-cell ingredient, is ready for commercial licensing, the second product from its Botanical Synthesis technology to reach that stage. The company said Olive Cell has completed large-scale bioreactor scale-up, manufacturing readiness and a self-affirmed U.S. Generally Recognized as Safe (GRAS) process.

Proactive Investors

BioHarvest Advances Proprietary Olive Cell Asset to Commercial Readiness, Opening New CDMO Licensing Opportunity

Botanical Synthesis™-developed asset has now completed development, commercial-scale manufacturing and the applicable self-affirmed GRAS process and is ready for production at BioHarvest's GMP facility Milestone demonstrates BioHarvest's ability to create proprietary plant-derived assets and advance them from plant-cell development through industrial manufacturing and commercialization High-potency proprietary olive-derived Verbascoside composition demonstrates promising dose-dependent preclinical activity across liver steatosis and fibrosis models, with potential for development across multiple health and wellness categories Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - October 13, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (TASE: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a biotechnology company pioneering its proprietary Botanical Synthesis™ technology, today announced that its proprietary Olive Cell composition (Olive Cell) has reached commercial readiness and is now available for licensing and commercialization through the Company's CDMO business. This milestone marks the completion of BioHarvest's development pathway for Olive Cell - from plant-cell development and optimization through large-scale bioreactor scale-up, commercial manufacturing readiness and completion of the applicable self-affirmed U.S. Generally Recognized as Safe ("GRAS") process.

Newsfile Corp

BioHarvest says its platform can produce target sweetener in Tate & Lyle program

BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said on Thursday its Botanical Synthesis platform can produce the next-generation sweetener targeted in its joint development program with Tate & Lyle. Tate & Lyle, a supplier of ingredient solutions for food and beverages, is looking to broaden its range of sweeteners as manufacturers seek ways to cut sugar and calories without losing taste and functionality, the companies said.

Proactive Investors

Tate & Lyle and Bioharvest Reach Key Milestone in Next-Generation Sweetener Development Programme

Progress demonstrates that BioHarvest's Botanical Synthesis(TM) platform is capable of producing the targeted next-generation sweetening solution Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - October 8, 2026) - Tate & Lyle PLC (Tate & Lyle), a global leader in ingredient solutions for healthier food and beverages, and BioHarvest Sciences Inc. (NASDAQ: BHST) (TASE: BHST) (BioHarvest), today announced an important milestone in their next-generation sweetener development programme. The programme has demonstrated that BioHarvest's Botanical Synthesis™ platform is capable of producing the targeted next-generation sweetening solution.

Newsfile Corp

BioHarvest Sciences launches buyback of up to 5% of shares

BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said Tuesday its board has authorized a share repurchase program covering up to 5% of its outstanding common shares. The company, which develops and manufactures proprietary plant-based compositions for customers, partners and its own portfolio, will structure the program as a normal course issuer bid, in line with Canadian practice.

Proactive Investors

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-14	-0.13	-0.11	0.02
2026-03-31	-0.105	-0.1	0.005
2025-11-13	-0.14	-0.14	0
2025-08-11	-0.11	-0.15	-0.04
2025-05-15	-0.15	-0.13	0.02
2025-03-31	-0.12	-0.17	-0.05
2024-11-25	-0.05	-0.16	-0.11
2024-10-23	-0.1	-0.04202	0.05798